DOCSLIB.ORG

Sidney Pestka, MD Dr. Sidney Pestka Received His Undergraduate Degree

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sidney Pestka, MD Dr. Sidney Pestka Received His Undergraduate Degree Sidney Pestka, MD Dr. Sidney Pestka received his undergraduate degree in chemistry from Princeton University in 1957 and his medical degree from the University of Pennsylvania School of Medicine in 1961. After completing a pediatric and medical internship at Baltimore City Hospitals, in 1962 he took a position in the laboratory of Dr. Marshall W. Nirenberg at the National Heart Institute, where he was part of the team working on research involving the genetic code, protein synthesis and ribosome function that led to the Nobel Prize in Physiology or Medicine received by Dr. Nirenberg. While in the Nirenberg Laboratory, Dr. Pestka discovered how the genetic code of the mRNA is translated into protein through the small ribosomal subunit, a surprising discovery that was contrary to the scientific thinking at that time. This early work helped create new fundamental tenets about the mechanism of protein biosynthesis and antibiotic action. In 1966, Dr. Pestka moved to the National Cancer Institute, where for three years he continued his research on protein synthesis and began investigations in other areas. In 1969, he joined the Roche Institute of Molecular Biology in Nutley, New Jersey, where he initiated the work on interferon. Dr. Pestka's breakthroughs have made an enormous impact on the biotechnology and pharmaceutical industries and on the development of new biotherapeutics for medicine. His work is the basis of a number of U.S. and more than 100 foreign patents. Interferon is a major product of several U.S. companies and foreign companies almost all of which license interferon under Dr. Pestka's patents, including Schering-Plough, Hoffmann-La Roche, Amgen, Biogen and Berlex. In recognition of his work, Dr. Pestka was awarded the nations highest honor for technological achievement, The National Medal of Technology, by President Bush at a White House ceremony in June 2002. Dr. Pestka was cited for his "pioneering achievements that led to the development of the biotechnology industry, to the first recombinant interferons for the treatment of cancers, leukemias, viral diseases such as hepatitis B and C, and multiple sclerosis; to fundamental technologies leading to other biotherapeutics; and for basic scientific discoveries in chemistry, biochemistry, genetic engineering and molecular biology from protein biosynthesis to receptors and cell signaling." Dr. Pestka was inducted into the New Jersey Inventors Hall of Fame in 1993, and has received many awards for his research including the National Medal of Technology in 2002, the Warren Alpert Prize from Harvard in 2004, the Selman Waksman Award in Microbiology and the Milstein Award from the International Society for Interferon and Cyokine Research. He has published over 300 articles in peer-reviewed journals; edited five books, three of which are classic reference books about interferons in the Methods of Enzymology series. His work with IFN-a has led to cancer therapy with interferons and the use of interferon for the treatment of chronic hepatitis B and C preventing development of liver cancer due to hepatitis. IFN-a is approved for treatment of a number of cancers and is the only approved treatment for advanced melanoma. His developments related to IFN-b led to its use for the treatment of multiple sclerosis. Dr. Pestka has been Chairman of the Board and Chief Scientific Officer of PBL Biomedical laboratories since 1990; and has been professor and chairman of the Department of Molecular Genetics, Microbiology and Immunology at UMDNJ-Robert Wood Johnson Medical School in Piscataway since 1986..
Load more

Recommended publications
  • Robert Wood Johnson Medical School Retired Faculty Association Newsletter
    ROBERT WOOD JOHNSON MEDICAL SCHOOL RETIRED FACULTY ASSOCIATION NEWSLETTER JANUARY 2017 VOLUME X, NO. 1 UPCOMING RFA MEETING IN VITRO FERTILIZATION: AN EMBRYONIC HISTORY “A Robot’s View of Our Ocean Planet” By Eckhard Kemmann, MD When I started my training in Obstetrics- Gynecology at SUNY Downstate-Kings County Hospital in Brooklyn almost five decades ago, infertility was encountered by ten percent of couples, and treatment options were limited and primarily surgical. My teachers and mentors at the institution represented different aspects of the presently evolving field of reproductive medicine. Dr. A. Siegler was a pioneer in tubal surgery and laparoscopy – in the 80s he would introduce laparoscopy to China. Dr. J. R. Jones was an early expert in reproductive hormone research, and Dr. A. Gemzell had come from Sweden where he faced mandatory retirement at the age of 65 and brought his expertise to the United States in the use of ovulation induction. Dr. Gemzell was the first to isolate and use (continued on page 2) Josh Kohut, Ph.D. Associate Professor, Department of Marine TABLE OF CONTENTS PAGE and Coastal Science, Rutgers University Upcoming Meeting 1 InT Vitro Fertilization: An Embryonic History Friday, March 3, 2017 by Eckhard Kemmann, MD 1 Noon – 1:30 p.m. Dean’s Conference Room I See You by Elliot Sultanik, MD, Class of 2016 4 Rutgers Robert Wood Johnson Medical School RWJMS RFA Election Results 5 Piscataway, New Jersey Retired RWJMS Faculty Program to Mentor Medical Students 5 All current and retired faculty, staff, and students Faculty Transition to Retirement Program 6 are welcome to attend.
    [Show full text]
  • Sidney Pestka Sid Died Dec. 22, 2016, Surrounded by Family. The
    Sidney Pestka Sid died Dec. 22, 2016, surrounded by family. The quintessential scientist since adolescence, he had been afflicted with dementia for the last few years of his life. Born in Drobin, Poland, at 21 months of age he moved near family to the Williamsburg neighborhood of Brooklyn, and then at age 8 to Trenton, where he excelled at Trenton Central High School. He received a scholarship to Princeton University, from where he graduated summa cum laude with a B.A. in chemistry. He received his medical degree from the University of Pennsylvania School of Medicine on full scholarship. Afterwards, he worked at the National Institutes of Health in the laboratory of Marshall W. Nirenberg. Sid’s early work on the genetic code, protein synthesis and ribosome function led to Nirenberg’s 1968 Nobel Prize in Physiology or Medicine. In 1969, Sid left the NIH for the Roche Institute of Molecular Biology, where he focused on defining how antibiotics worked and proteins are synthesized and, later, interferons. There he was first to purify interferon alpha and beta; the first to clone mature interferons; and the first to develop a commercialized recombinant biotherapeutic—Roferon A. Sid is known as the "Father of Interferon" for his seminal work on interferon, work that gave birth to a $6 billion dollar market directed at the therapy of hepatitis, multiple sclerosis, cancer, and other diseases that affect mankind. Sid was Emeritus Professor of the Department of Biochemistry and Molecular Biology at Robert Wood Johnson Medical School of Rutgers, The State University of New Jersey, which he joined in 1986 and where he served as Chairman for 25 years.
    [Show full text]
  • NJ's Top 10 Scientists
    NJ’s Top 10 Scientists here are more than 400,000 scientists and engineers in New Jersey hard at work each day delivering breakthrough medicines and technologies that save lives, improve our quality of life and keep our T economy competitive. With the cooperation of the leading technology trade associations in the state, New Jersey Business magazine is proud to present who we think are the “cream of the crop” in innovation: NJ’s Top 10 Scientists. Through their hard work and dedication, these men and women have made significant contributions to their companies, research institutions and society at large. Whether it is a biotechnology drug that helps fight cancer or AIDS, or a new kind of organic, light-emitting device that is four times more efficient than liquid crystal displays, these and other innovations from the scientists profiled are testaments to the research and development work being conducted in “The Innovative State”. We extend our appreciation to The Healthcare Institute of New Jersey, BioNJ, The New Jersey Research & Development Council, the New Jersey Technology Council and the Chemical Council of New Jersey for their assistance in gathering the nominations. The editors at New Jersey Business selected the final winners based on the impact their work has on society at large. A special recognition is being given to one scientist who, after the judging was completed, announced his retirement. Here, we present the innovators in alphabetical order: SPECIAL RECOGNITION Magid Abou-Gharbia, Ph.D., Senior Vice President and Head (Retired), Chemical and Screening Sciences, Wyeth Drug Discovery and Development, South Brunswick, NJ In October, Magid Abou-Gharbia, Ph.D., retired after 26 years with Wyeth Drug Discovery and Development – but not before leaving his mark in the pharmaceutical industry.
    [Show full text]
  • Milestones and Personalities in Science and Technology
    History of Science Stories and anecdotes about famous – and not-so-famous – milestones and personalities in science and technology BUILDING BETTER SCIENCE AGILENT AND YOU For teaching purpose only December 19, 2016 © Agilent Technologies, Inc. 2016 1 Agilent Technologies is committed to the educational community and is willing to provide access to company-owned material contained herein. This slide set is created by Agilent Technologies. The usage of the slides is limited to teaching purpose only. These materials and the information contained herein are accepted “as is” and Agilent makes no representations or warranties of any kind with respect to the materials and disclaims any responsibility for them as may be used or reproduced by you. Agilent will not be liable for any damages resulting from or in connection with your use, copying or disclosure of the materials contained herein. You agree to indemnify and hold Agilent harmless for any claims incurred by Agilent as a result of your use or reproduction of these materials. In case pictures, sketches or drawings should be used for any other purpose please contact Agilent Technologies a priori. For teaching purpose only December 19, 2016 © Agilent Technologies, Inc. 2016 2 Table of Contents The Father of Modern Chemistry The Man Who Discovered Vitamin C Tags: Antoine-Laurent de Lavoisier, chemical nomenclature Tags: Albert Szent-Györgyi, L-ascorbic acid He Discovered an Entire Area of the Periodic Table The Discovery of Insulin Tags: Sir William Ramsay, noble gas Tags: Frederick Banting,
    [Show full text]
  • A-Interferon Structure and Natural Killer Cell Stimulatory Activity1
    [CANCER RESEARCH 50. 5328-5332, September 1, 1990] a-Interferon Structure and Natural Killer Cell Stimulatory Activity1 Bo-Liang Li,2 Xiao-Xia Zhao,3 Xin-Yuan Liu,2 Hyon Suk Kim, Karel Raska, Jr., John R. Ortaldo, Barbara Schwartz, and Sidney Pestka4 Departments of Molecular Genetics and Microbiology [B.-L. L., X-X. Z.. X-Y. L., B. S., S. P.] and Pathology [H. S. A., A'. R.J, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, Sew Jersey 08854, and National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland 217011J. R.O.I ABSTRACT chased from New England BioLabs, T4 DNA ligase from International Biotechnologies Inc., polynucleotide kinase and deoxyribonucleotide Expression vectors for human a-interferon (Hu-IFN-a) .11. a site- triphosphates from P-L Biochemicals, and [«-"SjATP and [7-12P]ATP specific mutant |Ser"6]Hu-IFN-aJl, and Hu-IFN-aJ/C or Hu-IFN-aC/ from Amersham Corporation. J hybrids were constructed and expressed in Escherichìacoli. These Oligonucleotide-directed Site-specific Mutagenesis. M13mp8 Rf interferons and others were purified by immunoaffinity chromatography DN A was digested with £coRIand Hindi (Fig. 1) and then precipitated with a monoclonal antibody against human a-interferon. Their antiviral by equal volumes of 13% polyethylene glycol/1.6 M NaCl (9). The activity and ability to stimulate natural killer cell activity were determined precipitate was dissolved in 0.01 M Tris •HCl,pH 7.5-1.0 IHMEDTA) in comparison to several other human interferons. These results provide and ligated to the J689 fragment from the Hu-IFN-aJl gene (1, 10, some insight into structure-activity relationships for stimulating natural 11) under the following conditions: 100 ng of M13mpl8 Rf DNA killer cells and confirm our previous conclusions that antiviral activity vector fragment (EcoRl/Hincl\), 10-40 ng of fragment J689, and 0.9 cannot be used to predict other activities for an individual IFN-a species.
    [Show full text]
  • PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page
    Program Director/Principal Investigator (Last, First, Middle): BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Emine Ercikan Abali Associate Professor of Biochemistry, eRA COMMONS USER NAME (credential, e.g., agency login) Pharmacology and Medicine ABALIEM EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) INSTITUTION AND LOCATION DEGREE MM/YY FIELD OF STUDY (if applicable) University of Southwestern Louisiana, Lafayette, LA B.Sc. 1982-1986 Chemistry University of Southwestern Louisiana, Lafayette, LA M.S. 1988-1988 Chemistry The Ohio State University, Columbus, OH Ph.D. student 1989-1990 Chemistry Cornell University Graduate School of Medical Ph.D. 1990-1996 Pharmacology Sciences and Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, NY, NY Postdoc 1996-1998 Molecular Therapeutics Columbia University, NY, NY Postdoc 1998-1999 Biological Sciences (10months) A. Personal Background The overall aim of this project is to use dihydrofolate reductase (DHFR) as a prototype for other NAD(P) binding dehydrogenases to identify novel NAD(P) analogues that specifically target the NADPH binding site of DHFR as potent inhibitors of cancer cells. Specifically, we plan to investigate metabolism of NADPS in cell lines and in xenograft animal and to perform in silico screening of the NADPH binding site to identify potential new inhibitors targeted to DHFR. Lastly, we will determine further characterize the mechanism of action of NADPS in accelerating the degradation of DHFR in order to address development of drug-resistance to this new class of inhibitors.
    [Show full text]
  • History of Microbiology Milton Wainwright University of Sheffield Joshua Lederbergl the Rockefeller University
    History of Microbiology Milton Wainwright University of Sheffield Joshua Lederbergl The Rockefeller University I. Observations without Application ness of the nature and etiology of disease, with the II. The Spontaneous Generation Controversy result that the majority of the traditional killer dis- III. Tools of the Trade eases have now been conquered. Similar strides IV. Microorganisms as Causal Agents of have been made in the use of microorganisms in Disease industry. and more recently attempts are being made V. Chemotherapy and Antibiosis to apply our knowledge of microbial ecology and VI. Microbial Metabolism and Applied physiology to help solve environmental problems. A Microbiology dramatic development and broadening of the subject VII. Nutrition, Comparative Biochemistry, and of microbiology has taken place since World War II. Other Aspects of Metabolism Microbial genetics, molecular biology, and bio- VIII. Microbial Genetics technology in particular have blossomed. It is to be IX. Viruses and Lysogeny: The Plasmid hoped that these developments are sufficiently op- Concept portune to enable us to conquer the latest specter of X. Virology disease facing us, namely AIDS. Any account of the XI. Mycology and Protozoology, history of a discipline is. by its very nature, a per- Microbiology’s Cinderellas sonal view: hopefully, what follows includes all the XII. Modern Period major highlights in the development of our science. The period approximating 1930-1950 was a ‘vi- cennium” of extraordinary transformation of micro- Glossary biology, just prior to the landmark publication on the structure of DNA by Watson and Crick in 1953. Antibiotics Antimicrobial agents produced b) We have important milestones for the vicennium: living organisms Jordan and Falk (1928) and “System of Bacteriol- Bacterial genetics Study of genetic elements and ogy” (1930) at its start are magisterial reviews of hereditary in bacteria prior knowledge and thought.
    [Show full text]
  • Extensions of Remarks E1059 HON. NANCY L. JOHNSON HON. FRANK
    June 14, 2002 CONGRESSIONAL RECORD — Extensions of Remarks E1059 HONORING LOUISE BELKIN, FRANK and introduced the ‘‘Invention Convention’’ the now used in the clinic and stimulated the cre- JOSLYN, AND TERRY WERDEN West District School’s Grade 5. She also has ation and development of today’s extensive FOR THEIR OUTSTANDING SERV- given her time as an active member of the biotechnology industry. Dr. Pestka’s achieve- ICE AND DEDICATION TO TEACH- Farmington Education Association, and as a ments are the basis of several U.S. and for- ING AT THE WEST DISTRICT member of curriculum teams for writing, eign patents and interferon is now a major SCHOOL IN FARMINGTON, CON- science and social studies. She currently has product of several U.S. and foreign compa- NECTICUT three students whose parents she also taught nies. The market for interferon is expected to in the Farmington School system. Mrs. exceed $7 billion by 2003. HON. NANCY L. JOHNSON Werden is a dedicated public servant and her In addition to interferon’s commercial im- OF CONNECTICUT influence has been strongly felt throughout pact, there was no general antiviral therapy IN THE HOUSE OF REPRESENTATIVES West District School and the families it serves. available before Dr. Pestka began his work on Her presence within our walls will be greatly interferon; today, interferon is the first and only Thursday, June 13, 2002 missed, as she moves on to teach at Farming- general antiviral therapy. Interferon is used to Mrs. JOHNSON of Connecticut. Mr. Speak- ton’s new 5–6 school. treat hepatitis B and C, diseases that afflict er, I rise today to acknowledge the achieve- These three educators have served on the 300 million people worldwide.
    [Show full text]
  • June 2021 Issue
    SIMB News News Magazine of the Society for Industrial Microbiology and Biotechnology April/May/June 2021 V.71 N.2 • www.simbhq.org The Microbiology of Sheer Fun A Memorial to Douglas E. Eveleigh RAFT® returns to the Hyatt 2021 RAFT® Chairs: Regency Coconut Point Mark Berge, AstraZeneca November 7–10, 2021 Kat Allikian, Mythic Hyatt Regency Coconut Mushrooms Point, Bonita Springs, FL www.simbhq.org/raft contents 34 CORPORATE MEMBERS SIMB News 35 LETTER FROM THE EDITOR-IN-CHIEF Melanie Mormile | Editor-in-Chief 36 SIMB STRATEGIC PLAN Elisabeth Elder | Associate Editor Kristien Mortelmans | Associate Editor 38 NEWSWORTHY Vanessa Nepomuceno | Associate Editor 44 FEATURE: DESIGN & PRODUCTION Katherine Devins | Production Manager THE MICROBIOLOGY OF SHEER FUN: A MEMORIAL TO DOUGLAS E. EVELEIGH (1933–2019) BOARD OF DIRECTORS President Steve Decker 60 SBFC 2021 RECAP President-elect Noel Fong 61 SIMB ANNUAL MEETING 2021 Past President Jan Westpheling 62 RAFT® 14 2021 Secretary Elisabeth Elder SIMB WORKSHOPS Treasurer Laura Jarboe 64 Directors Rob Donofrio 65 INDUSTRIAL MICROBIOLOGY MEETS THE MICROBIOME (IMMM) 2021 Katy Kao Priti Pharkya 68 BOOK REVIEW: Tiffany Rau CLIMATE CHANGE AND MICROBIAL ECOLOGY: CURRENT RESEARCH HEADQUARTERS STAFF AND FUTURE TRENDS (SECOND EDITION) Christine Lowe | Executive Director Jennifer Johnson | Director of Member Services 71 CALENDAR OF EVENTS Tina Hockaday | Meeting Coordinator Suzannah Citrenbaum | Web Manager 73 SIMB COMMITTEE LIST SIMB CORPORATE MEMBERSHIP APPLICATION EDITORIAL CORRESPONDENCE 75 Melanie R. Mormile Email: [email protected] ADVERTISING For information regarding rates, contact SIMB News 3929 Old Lee Highway, Suite 92A Fairfax, VA 22030-2421 P: 703-691-3357 ext 30 F:703-691-7991 On the cover Email: [email protected] Doug Eveleigh wearing his father’s www.simbhq.org bowler hat while examining lichens SIMB News (ISSN 1043-4976), is published quarterly, one volume per year, by the on a tombstone.
    [Show full text]
  • Contributions of Cloned Type I Interferon Receptor Subunits to Differential Ligand Binding
    FEBS 18274 FEBS Letters 404 (1997) 197-202 Contributions of cloned type I interferon receptor subunits to differential ligand binding Elizabeth Cali Cutronea, Jerome A. Langera'b'* aDepartment of Molecular Genetics and Microbiology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA h Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA Received 20 January 1997 IFNAR-1) [5] has weak intrinsic affinity for at least two Abstract The human type I interferons, including at least 12 IFN-as, IFN-P and IFN-co, bind to a receptor (IFNAR) IFNs, IFN-a2 and -a8 [6,7]. Its expression confers on rodent composed of at least two transmembrane subunits, IFNAR-1 cells limited responsiveness and binding of human type I IFNs and IFNAR-2. The contributions of the receptor subunits to [5], and enhances the ability of monkey-derived COS cells to ligand binding were investigated by measuring the binding bind human IFNs [8]. In contrast to HuIFNAR-1, the bovine properties of IFNAR-1 or IFNAR-2 alone, or when co- homologue (BoIFNAR-1) fortuitously binds human IFN-as expressed. The affinity of IFNAR-2 for IFN-ct2 was increased with high affinity [6,9,10]. The ability of antibodies against by the co-expression of IFNAR-1, which itself binds ligand very HuIFNAR-1 to block the binding of various type I interfer- weakly. Most type I IFNs inhibited the binding of IFN-ot2 to ons to human cells [11,12] suggests that IFNAR-1 is involved IFNAR-2 alone with IC50 values of 2-20 nM.
    [Show full text]
  • Sydney Udenfriend 1918– 1999
    NATIONAL ACADEMY OF SCIENCES SYDNEY UDENFRIEND 1918– 1999 A Biographical Memoir by HERBERT WEISSBACH AND BERNHARD WITKOP Any opinions expressed in this memoir are those of the authors and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoirs, VOLUME 83 PUBLISHED 2003 BY THE NATIONAL ACADEMIES PRESS WASHINGTON, D.C. Taken from the Annual Report of the Roche Institute of Molecular Biology SIDNEY UDENFRIEND April 5, 1918–December 29, 1999 BY HERBERT WEISSBACH AND BERNHARD WITKOP IDNEY UDENFRIEND’S PARENTS emigrated to the United S States from an Austro-Polish region in central Eu- rope in 1913. They had three children; the oldest was Sidney, who was born in Brooklyn, New York, on April 5, 1918. After attending public schools in Brooklyn Udenfriend en- tered the City College of New York (CCNY) in 1935. At that time CCNY was the dream for so many of the immigrant parents who wanted their children to obtain a college edu- cation. Supported by public funds, with no tuition, CCNY provided that opportunity for those students who could pass the rigid requirements for entrance. The Chemistry De- partment was well recognized in the field of physiological chemistry (or biochemistry) thanks in large part to Ben- jamin Harrow, who wrote a widely used textbook. Harrow had a great influence on Udenfriend, and after graduation in 1939 Udenfriend was set on a career in bio- chemistry and determined to go to graduate school. In 1940 he was accepted at New York University Graduate School in the Department of Biology working with Kenneth Blanchard.
    [Show full text]
  • Selman Waksman and Antibiotics Selman Waksman and Antibiotics
    You are here: » American Chemical Society » Education » Explore Chemistry » Chemical Landmarks » Selman Waksman and Antibiotics Selman Waksman and Antibiotics National Historic Chemical Landmark Dedicated May 24, 2005, at Rutgers The State University of New Jersey. Commemorative Booklet (PDF) Waksman and his students, in their laboratory at Rutgers University, established the first screening protocols to detect antimicrobial agents produced by microorganisms. This deliberate search for chemotherapeutic agents contrasts with the discovery of penicillin, which came through a chance observation by Alexander Fleming, who noted that a mold contaminant on a Petri dish culture had inhibited the growth of a bacterial pathogen. During the 1940s, Waksman and his students isolated more than fifteen antibiotics, the most famous of which was streptomycin, the first effective treatment for tuberculosis. Contents Selman Waksman’s Early Years Waksman Moves to America Waksman’s Research on Actinomycetes, and the Search for Antibiotics The Trials of Streptomycin Bringing Streptomycin to Market Controversy over the Discovery of Streptomycin Selman Waksman’s Later Years Research Notes and Further Reading Landmark Designation and Acknowledgments Cite this Page “Selman Waksman and Antibiotics” commemorative booklet produced by the National Historic Chemical Landmarks program of the American Chemical Society in 2005 (PDF). "The Lord hath created medicines out of the earth; and he that is wise will not abhor them." — Ecclesiasticus, xxxviii, 41 Selman Waksman’s Early Life Selman Waksman called his autobiography My Life with the Microbes. That is also the title of the first chapter of the book, which begins "I have devoted my life to the study of microbes, those infinitesimal forms of life which play such important roles in the life of man, animals, and plants.
    [Show full text]